DISPROPORTIONATE GROWTH FOLLOWING LONG-TERM GROWTH-HORMONE TREATMENT IN SHORT CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA
DISPROPORTIONATE GROWTH FOLLOWING LONG-TERM GROWTH-HORMONE TREATMENT IN SHORT CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA
复制标题
DOI：
10.1007/bf02079060
复制
发表时间：
1995-08-01
影响因子：
3.6
通讯作者：
MEHLS, O
中科院分区：
文献类型：
--
作者：
HAFFNER, D;WUHL, E;MEHLS, O
三个短的青春期前的儿童与X连锁低磷血症治疗1 IU重组人生长激素（rhGH）/公斤，每周皮下注射，除了骨化三醇和磷酸盐补充超过3年。身高标准差评分（SDS）的改善范围为1.0-1.7 SD，基于坐高增加1.5-2.9 SD，而坐骨下腿长仅轻微改善0.3-0.9 SD。在所有三名患者中，肾磷酸盐阈值浓度略有增加和短暂的甲状旁腺功能亢进notice.Conclusion治疗发育迟缓的儿童与X连锁低磷血症是有效的，在提高生长速度，但似乎加剧了预先存在的不成比例的身高，这样的孩子。
Three short prepubertal children with X-linked hypophosphataemia were treated with 1 IU recombinant human growth hormone (rhGH)/kg per week sc in addition to calcitriol and phosphate supplementation over a period of 3 years. Improvement of height standard deviation score (SDS) ranged from 1.0-1.7 SD based on an increase in sitting height of 1.5-2.9 SD, whereas subischial leg length improved only slightly by 0.3-0.9 SD. In all three patients, renal phosphate threshold concentration increased slightly and transient hyperparathyroidism was noted.Conclusion Treatment of stunted children with X-linked hypophosphataemia is effective in improving growth velocity, but appears to aggravate the pre-existent disproportionate stature of such children.